Effects of comedication on the serum levels of aripiprazole: Evidence from a routine therapeutic drug monitoring service

被引:36
作者
Castberg, I.
Spigset, O.
机构
[1] Univ Trondheim, St Olv Hosp, Dept Forens Psychiat Broset, N-7440 Trondheim, Norway
[2] Univ Trondheim, St Olv Hosp, Dept Clin Pharmacol, N-7440 Trondheim, Norway
[3] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway
[4] Norwegian Univ Sci & Technol, Dept Lab Med, N-7034 Trondheim, Norway
关键词
aripiprazole; therapeutic drug monitoring; drug interactions;
D O I
10.1055/s-2007-977715
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The objective of the study was to compare the serum concentrations of the atypical antipsychotic aripiprazole in monotherapy with the concentrations found during concomitant therapy with other drugs. Methods: Samples analyzed for aripiprazole by a liquid chromatography-mass spectrometry method in a routine therapeutic drug monitoring setting were collected consecutively. Results: Samples from 81 patients were included in the study. Comedication with the CYP3A4 inducer carbamazepine lowered the dose-adjusted aripiprazole concentration by 88%. Comedication with CYP2D6 inhibitors gave a mean concentration 44% higher than in the monotherapy group. Subjects comedicated with valproate had lower aripiprazole concentrations, while subjects comedicated with lamotrigine, citalopram/escitalopram and lithium had higher concentrations than the subjects in the monotherapy group. Conclusion: Although the study is small and the results should be interpreted very cautiously, it indicates that comedication with drugs inhibiting or inducing CYP2D6 or CYP3A4 affects the serum concentrations of aripiprazole. The other findings should be considered as preliminary and have to be replicated in a larger setting before firm conclusions can be drawn.
引用
收藏
页码:107 / 110
页数:4
相关论文
共 17 条
[1]   Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors [J].
Adson, DE ;
Kushner, MG ;
Fahnhorst, TA .
JOURNAL OF AFFECTIVE DISORDERS, 2005, 86 (01) :99-104
[2]   Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram [J].
Brosen, K ;
Naranjo, CA .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2001, 11 (04) :275-283
[3]   Pharmacokinetics of aripiprazole and concomitant lithium and valproate [J].
Citrome, L ;
Josiassen, R ;
Bark, N ;
Salazar, DE ;
Mallikaarjun, S .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (01) :89-93
[4]   The use of aripiprazole in obsessive-compulsive disorder: Preliminary observations in 8 patients [J].
Connor, KM ;
Payne, VM ;
Gadde, KM ;
Zhang, W ;
Davidson, JRT .
JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (01) :49-51
[5]  
Dickins M, 2002, ANTIEPILEPTIC DRUGS, P370
[6]   Aripiprazole for schizophrenia [J].
El-Sayeh, H. G. ;
Morganti, C. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (02)
[7]  
ELSAYED H, 2004, COCHRANE DB SYST REV
[8]   Aripiprazole:: Pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia [J].
Gründer, G ;
Kungel, M ;
Ebrecht, M ;
Göröcs, T ;
Modell, S .
PHARMACOPSYCHIATRY, 2006, 39 :S21-S25
[9]   Therapeutic monitoring of new antipsychotic drugs [J].
Hiemke, C ;
Dragicevic, A ;
Gründer, G ;
Hätter, S ;
Sachse, J ;
Vernaleken, I ;
Müller, MJ .
THERAPEUTIC DRUG MONITORING, 2004, 26 (02) :156-160
[10]   Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder [J].
Kane, JM ;
Carson, WH ;
Saha, AR ;
McQuade, RD ;
Ingenito, GG ;
Zimbroff, DL ;
Ali, MW .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (09) :763-771